Cite
HARVARD Citation
Rowley, A. et al. (n.d.). P359 A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration. Journal of Crohn's and colitis. pp. S285-S286. [Online].